← Leaderboards
Ronald Edward Viola
University Of Chicago
$3,115,440
Attributed
$3,312,682
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $551.1K · FY2005–14$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$3,312,682 · 4
By mechanism
R01$2,912,316 · 2
R21$394,485 · 1
P41$5,881 · 1
Top collaborators
- Robert Martin Blumenthal2 shared
Most similar at University Of Chicago
Same institution · by research overlap
- Laurie L Parker$8,784,661
- Yimin Zou$16,553,198
- Jing Chen$12,817,541
- Marc B Hershenson$21,013,981
- Marsha R Rosner$15,100,833
Others in their field
Top investigators on “Enzymes”
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$143,577,666
- Randall J Bateman · Washington University$83,824,814
- Stuart L Schreiber · Harvard University (Medical School)$49,424,554
- Jay D Keasling · University Of California-Berkeley$47,558,861
- David Heimbrook · Leidos Biomedical Research, Inc.$47,513,682
- Susan Abushakra · Alzheon, Inc.$47,265,244
Research focus
EnzymesResponseProgramsLeadInhibitor/AntagonistAspartatePropertyX Ray Diffraction AnalysisStructureMetabolicSpecificityComplexModificationX-Ray DiffractionBinding (Molecular Function)PhysiologicalLaboratoriesBaseEnzyme InhibitorsEnzyme Inhibitor DrugsCrystallizationSeriesAntibioticsOrganism
Grant awards (15)
Development of Aspartate Pathway Inhibitors as Novel Antibiotics$360,113
R01 · FY2014 · AI · contact PI
Development of Aspartate Pathway Inhibitors as Novel Antibiotics$338,506
R01 · FY2013 · AI · contact PI
Selective Agents to Block Virulence in Gram-negative Pathogens$212,610
R21 · FY2013 · AI · contact PI
Development of Aspartate Pathway Inhibitors as Novel Antibiotics$360,113
R01 · FY2012 · AI · contact PI
Selective Agents to Block Virulence in Gram-negative Pathogens$181,875
R21 · FY2012 · AI · contact PI
Development of Aspartate Pathway Inhibitors as Novel Antibiotics$351,689
R01 · FY2011 · AI · contact PI
Development of Aspartate Pathway Inhibitors as Novel Antibiotics$360,110
R01 · FY2010 · AI · contact PI
Probing the Enzymatic Basis of Canavan Disease$221,021
R01 · FY2009 · NS · contact PI
Probing the Enzymatic Basis of Canavan Disease$221,021
R01 · FY2008 · NS · contact PI
Probing the Enzymatic Basis of Canavan Disease$221,021
R01 · FY2007 · NS · contact PI
Probing the Enzymatic Basis of Canavan Disease$227,622
R01 · FY2006 · NS · contact PI
Probing the Enzymatic Basis of Canavan Disease$233,100
R01 · FY2005 · NS
Probing the Enzymatic Basis of Canavan Disease$18,000
R01 · FY2005 · NS
STRUCTURE OF ASPARTOKINASE - THE COMMITMENT TO THE ASPARTATE PATHWAY$3,391
P41 · FY2005 · RR
STRUCTURE OF ASPARTOKINASE/THE ASPARTATE PATHWAY$2,490
P41 · FY2004 · RR